disitamab vedotin + radiotherapy + PD-1 inhibitor + GM-CSF + IL-2

PRaG 3.0 is an investigational combination immunotherapy regimen being evaluated for the treatment of HER2-positive advanced refractory solid tumors. Developed as an investigator-initiated trial by the Second Affiliated Hospital of Soochow University, the regimen integrates disitamab vedotin (RC48-ADC)—a humanized anti-HER2 antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE)—with hypofractionated radiotherapy, a PD-1/PD-L1 inhibitor, and the sequential administration of the cytokines GM-CSF and IL-2. The mechanism of action involves direct HER2-targeted cell killing and payload-mediated microtubule inhibition, complemented by radiotherapy-induced immunogenic cell death and immune checkpoint blockade. The sequential addition of GM-CSF and IL-2 is intended to further stimulate dendritic cell maturation and T-cell proliferation, creating a robust anti-tumor immune response in patients who have failed standard therapies.

Brand names

Aidixi

Other names

o-Second Affiliated Hospital of Soochow University-solid tumorPRaG 3.0 regimenPRaG3.0 regimenPRaG-3.0 regimendisitamab vedotin combination therapyRC48-ADC combination therapyRC-48-ADC combination therapyRC 48-ADC combination therapy